Alumis Inc. reports clinical, financing and corporate updates as a late-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. Its pipeline centers on oral TYK2 inhibitors, including envudeucitinib for systemic immune-mediated disorders such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for neuroinflammatory and neurodegenerative diseases. The company also lists lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease, and preclinical programs identified through its precision approach.
Recurring ALMS news includes envudeucitinib clinical data from the ONWARD and STRIDE programs, disease-biomarker presentations, financial results, investor conference communications and common-stock financing activity.
Alumis (ALMS) will participate in four healthcare investor conferences in September 2026, featuring fireside chats and a presentation accessible via webcast.
The company will appear at the Wells Fargo, Cantor, Morgan Stanley and Baird healthcare conferences between September 8 and 15, with live and replay webcasts available on its investor website.
Alumis (Nasdaq: ALMS) reported topline Phase 2b LUMUS results for oral TYK2 inhibitor envudeucitinib in moderate-to-severe systemic lupus erythematosus (SLE). The overall trial population did not meet the primary BICLA endpoint or key secondary endpoints, including CLASI-50, SRI-4 and LLDAS.
According to Alumis, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust clinical responses across the primary and key secondary endpoints. Pharmacodynamic data demonstrated dose-dependent interferon-pathway target engagement, with maximal suppression at 40 mg twice daily. Envudeucitinib was generally well tolerated with no new safety signals. Alumis plans to engage regulators on Phase 3 SLE development, sees broader potential in interferon-driven diseases such as cutaneous lupus and Sjögren’s disease, and remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026. A webcast to review LUMUS data is scheduled for September 1, 2026 at 8:30 am EDT.
Alumis (Nasdaq: ALMS) reported second quarter 2026 results and clinical progress centered on TYK2 inhibitor envudeucitinib. In the ONWARD3 long-term extension psoriasis study, 75% and 54% of patients achieved PASI 90 and PASI 100, respectively, after up to 48 weeks of treatment (n=773), with a safety profile consistent with earlier ONWARD1/2 trials.
Alumis remains on track to submit a New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026 and expects potentially pivotal Phase 2b LUMUS topline data in SLE in Q3 2026. The company is prioritizing Sjögren’s disease and cutaneous lupus erythematosus as additional interferon-driven indications and plans a Phase 2 biomarker trial for CNS-penetrant TYK2 inhibitor A-005 in Parkinson’s disease in 1H 2027. Alumis will explore strategic alternatives for the lonigutamab program.
For Q2 2026, Alumis reported revenue of $1.7 million, R&D expenses of $85.3 million and G&A expenses of $23.4 million, plus a $41.8 million impairment of the lonigutamab IPR&D asset, leading to a net loss of $142.2 million. Cash, cash equivalents and marketable securities totaled $502.3 million, which are expected to fund operations into Q4 2027.
Alumis (Nasdaq: ALMS) reported topline 48-week data from the ONWARD3 long-term extension study of investigational oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis. In a non-responder imputation analysis of 773 continuously treated patients, 75% achieved PASI 90 and 54% achieved PASI 100 skin clearance.
According to Alumis, these are the highest reported PASI 100 rates among existing and investigational oral therapies, with approximately 90% and 80% of patients sustaining PASI 90 and PASI 100, respectively. An integrated analysis across 890 patients showed 66% PASI 90 and 47% PASI 100 at 48 weeks. The safety profile remained consistent with prior trials, and the company plans a U.S. NDA submission in 4Q 2026.
Alumis (Nasdaq: ALMS) reported Q1 2026 results and key clinical progress. Envudeucitinib Phase 3 psoriasis data showed PASI 90 responses of 68.0% and 62.1% and PASI 100 responses of 41.0% and 39.5%, with favorable safety, supporting a planned NDA submission in 4Q 2026.
Potentially pivotal Phase 2b SLE topline data are expected in 3Q 2026. Alumis ended March 31, 2026 with $569.5M in cash, cash equivalents and marketable securities, Q1 revenue of $1.7M versus $17.4M a year earlier, R&D expenses of $81.5M, G&A of $18.6M, and a net loss of $93.1M. Existing cash is expected to fund operations into 4Q 2027; the company is exploring strategic alternatives for lonigutamab.
Alumis (Nasdaq: ALMS) reported Phase 3 ONWARD1 and ONWARD2 results for oral TYK2 inhibitor envudeucitinib, showing rapid, deep skin clearance and symptom relief. PASI 90 reached 68.0% and 62.1% at Week 24; PASI 100 reached 41.0% and 39.5% at Week 24.
Quality-of-life and itch improved early (DLQI ~50% at Week 12; >4-point itch improvement by Week 16). Safety was consistent with Phase 2. Alumis plans an NDA submission in H2 2026 and continues ONWARD3 extension.
Alumis (Nasdaq: ALMS) reported year-end 2025 results and clinical progress for envudeucitinib, highlighting positive Phase 3 ONWARD1/ONWARD2 topline results in moderate-to-severe plaque psoriasis with ~65% PASI 90 and >40% PASI 100 at Week 24.
The company closed an upsized public offering raising ~$345.1 million gross, held $308.5 million cash and expects to fund operations into Q4 2027; an NDA submission is planned in 2H 2026 and potential SLE Phase 2b topline data are anticipated in 3Q 2026.
Alumis (Nasdaq: ALMS) announced that Phase 3 ONWARD 1 and 2 results for envudeucitinib will be presented as a late‑breaking oral presentation at the 2026 AAD Annual Meeting on March 28, 2026, at 11:12 am MDT.
A Phase 2 STRIDE biomarker analysis will appear as an e‑poster (poster 73714). Alumis will host an investor webcast on March 29, 2026 at 5:00 pm MDT to review the ONWARD data; presentations and a replay will be posted on the company website on March 28–29, 2026.
Alumis (Nasdaq: ALMS) announced that CEO Martin Babler will speak at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 10:40 a.m. ET. A live webcast will be available on the company's Investors > Events page, and a replay will be archived for 90 days.
Alumis (Nasdaq: ALMS) will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook: Biotech Summit on February 11-12 in New York with a fireside chat on February 12 at 9:00 AM ET, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26 with a presentation on February 26 at 3:20 PM ET.
Live webcasts will be available on the company’s Investors > Events page, and replay archives will remain on the website for 90 days.